Predict your next investment

Merchant Bank
piedmontcapitalpartners.com

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

About Piedmont Capital Partners

Piedmont Capital Partners is a Merchant Banking firm, located in Glen Allen, Virginia. The firm was created in 2005 with the goal of drawing on the prior 20 plus years of merchant banking, corporate development, investment and finance experience of the firm's Managing Partner, Stan Manoogian.

Piedmont Capital Partners Headquarter Location

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Piedmont Capital Partners News

AsclepiX Therapeutics Raises $5M in Funding

Nov 13, 2018

AsclepiX Therapeutics, Inc. , a Baltimore, MD-based biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform, raised $5m in convertible note funding. The round was led by Barer & Son Capital with participation from Rapha Capital Management, Salem Partners, TEDCO, and Piedmont Capital Partners. In conjunction with the funding, AsclepiX expanded its board to add Josh Barer, Kevin Slawin, MD, and Sapna Srivastava, PhD, to the founding members Aleksander Popel, PhD and Jordan J. The company intends to use the funds to accelerate development of AXT107, its innovative treatment for two leading causes of adult blindness: – diabetic macular edema (DME) and – wet age-related macular degeneration (wet AMD). Led by CEO Perrow, AsclepiX Therapeutics is advancing a treatment of ocular diseases and cancer focusing on a novel peptide platform which inhibits and potentially reverse disease progression. The mechanism of action of AXT107 targets multiple pathways, including vascular endothelial growth factor A (VEGF-A) and Tie2, two factors that promote formation of blood vessels and leakage of fluid in the diseased retina. The company is initially focused on ocular diseases currently treated with anti-VEGF monotherapies. FinSMEs 13/11/2018

Piedmont Capital Partners Investments

6 Investments

Piedmont Capital Partners has made 6 investments. Their latest investment was in Posh as part of their Series A on December 12, 2021.

CBI Logo

Piedmont Capital Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/9/2021

Series A

Posh

$27.5M

Yes

14

10/13/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/13/2018

Convertible Note

Subscribe to see more

$99M

Subscribe to see more

10

1/2/2018

Series A

Subscribe to see more

$99M

Subscribe to see more

10

6/1/2017

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/9/2021

10/13/2020

11/13/2018

1/2/2018

6/1/2017

Round

Series A

Series B

Convertible Note

Series A

Series B

Company

Posh

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$27.5M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

14

10

10

10

10

Piedmont Capital Partners Portfolio Exits

1 Portfolio Exit

Piedmont Capital Partners has 1 portfolio exit. Their latest portfolio exit was NexImmune on February 12, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/12/2021

IPO

$99M

Public

2

Date

2/12/2021

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

2

Piedmont Capital Partners Team

1 Team Member

Piedmont Capital Partners has 1 team member, including current Founder, Managing Partner, Louise Freemon Brady.

Name

Work History

Title

Status

Louise Freemon Brady

Founder, Managing Partner

Current

Name

Louise Freemon Brady

Work History

Title

Founder, Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.